Zhitong Finance App News, Changchun Hi-Tech (000661.SZ) issued an announcement. The company's subsidiary Changchun Baike Biotechnology Co., Ltd. (“Baike Biotech”) received the “Notice of Acceptance” of the marketing license application for a live attenuated nasal spray influenza vaccine issued by the Drug Evaluation Center of the State Drug Administration. The live attenuated nasal spray vaccine received by Baike Biotech this time can form the first immune barrier to prevent the influenza virus from invading the respiratory tract by simulating a natural influenza virus infection through nasal inoculation. The dosage form of the vaccine was improved on the basis of the live freeze-dried nasal spray influenza attenuated vaccine product already marketed by Baig Biotech. The original freeze-dried dosage form was upgraded to a liquid dosage form, making vaccination more convenient, and the applicable population was extended to people aged 3 to 59.